Akari Therapeutics Plc ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
46.7%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$8.01next fiscal year
Monitoring Framework
Key Performance Indicators
AKTX-101 IND/CTA Submission Timeline QuarterlyTarget: Late 2026 / Early 2027
AKTX-101 First-in-Human Phase 1 Clinical Trial Initiation QuarterlyTarget: Mid-2027
Cash and Restricted Cash Balance Quarterly2.8MTarget: Sufficient to fund operations beyond June 2026
Watch Items
- Going Concern and Liquidity RunwayTrigger: Cash runway estimated to fund operations only into June 2026Action: Utilize the $25 million White Lion Capital Equity Line of Credit (ELOC) or secure additional private placement financing to extend the operational runway.
- Nasdaq Minimum Bid Price ComplianceTrigger: ADS price falling below $1.00 for consecutive business daysAction: Monitor closing bid price and implement structural options, such as the ADS ratio change from 1:2,000 to 1:80,000 (effective March 31, 2026), to maintain listing requirements.
- AKTX-101 IND-Enabling Activities with WuXi XDCTrigger: Delays in GMP manufacturing or preclinical safety studiesAction: Coordinate closely with development partner WuXi XDC to ensure timely completion of IND-enabling work to support the mid-2027 Phase 1 trial target.
Research as of 20 Jun 2026